Article
Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma.
Cancer treatment reviews - 1 Nov 2010
Bronte Giuseppe, Rizzo Sergio, La Paglia Laura, Adamo Vincenzo, Siragusa Sergio, Ficorella Corrado, Santini Daniele, Bazan Viviana, Colucci Giuseppe, Gebbia Nicola, Russo Antonio
Abstract excerpt
The adenocarcinoma of the lung has recently shown peculiar molecular characteristics, which relate with both carcinogenesis and response to targeted drugs. Several molecular alterations have been defined as "driver mutations". These are responsible for both the initiation and maintenance of the malignancy. The epidermal growth factor receptor (EGFR) pathway is the main regulator of cell function and cancer...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.